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AbstrACt
Objective The objective of the study was to compare 
pregnancy outcomes according to maternal antiretroviral 
treatment (ART) regimens.
Design A retrospective cohort study.
Participants and settings Clinical data was extracted 
from ART exposed pregnancies of HIV-infected Ethiopian 
women attending antenatal care follow-up in public health 
facilities in Addis Ababa between February 2010 and 
October 2016.
Outcomes The primary outcomes evaluated were preterm 
birth, low birth weight and small-for-gestational-age.
results A total 1663 of pregnancies exposed to ART 
were included in the analyses. Of these pregnancies, 
17% resulted in a preterm birth, 19% in low birth weight 
and 32% in a small-for-gestational-age baby. Compared 
with highly active antiretroviral therapy (HAART) initiated 
during pregnancy, zidovudine monotherapy was less likely 
to result in preterm birth (adjusted OR 0.35, 95% CI 0.19 
to 0.64) and low birth weight (adjusted OR 0.48, 95% CI 
0.24 to 0.94). We observed no differential risk of preterm 
birth, low birth weight and small-for-gestational-age, when 
comparing women who initiated HAART during pregnancy 
to women who initiated HAART before conception. The risk 
for preterm birth was higher in pregnancies exposed to 
nevirapine-based HAART (adjusted OR 1.44, 95% CI 1.06 
to 1.96) compared with pregnancies exposed to efavirenz-
based HAART. Comparing nevirapine-based HAART with 
efavirenz-based HAART indicated no strong evidence of 
increased risk of low birth weight or small-for-gestational-
age.
Conclusions We observed a higher risk of preterm birth 
among women who initiated HAART during pregnancy 
compared with zidovudine monotherapy. Pregnancies 
exposed to nevirapine-based HAART also had a greater 
risk of preterm births compared with efavirenz-based 
HAART.
IntrODuCtIOn
Antiretroviral therapy (ART) is effective in 
reducing the risk of mother-to-child trans-
mission of HIV.1–3 Before 2013, HIV-infected 
pregnant women not eligible for highly 
active antiretroviral therapy (HAART) were 
given zidovudine/single-dose nevirapine 
(ZDV/SD NVP) or triple antiretroviral drugs 
as prophylaxis based on the WHO recom-
mendation. However, the WHO revised its 
recommendations to initiate HAART for all 
HIV-infected pregnant and breastfeeding 
women in 2013.4 This recommendation was 
further revised to include universal treat-
ment to all HIV-infected individuals in 2015.5 
Studies comparing the safety of HAART 
versus ZDV monotherapy during preg-
nancy report inconsistent findings related 
to preterm birth, where some studies indi-
cate a greater risk of preterm birth associ-
ated with HAART,6–13 and some indicated 
that the greater risk of preterm birth may be 
specific to HAART with protease inhibitors 
(PIs),14–16 while others reported no strong 
evidence for an association.17–19 Some studies 
have also reported increased risk of low birth 
weight,6 11 15 and small-for-gestational-age,10 
among women taking HAART as compared 
women taking ZDV monotherapy during 
pregnancy, but majority of studies show no 
evidence of an association.14 18 20–24 
Several studies compared safety of 
PI-based HAARTs with other type of HAART 
strength and limitation of this study
 ► This study is the first to evaluate pregnancy out-
comes according to different antiretroviral therapies 
in Ethiopia.
 ► Prospectively collected information on antiretrovi-
ral treatment and effectiveness was extracted from 
women’s medical records.
 ► The study was conducted in an urban setting and 
may therefore not be generalisable to women living 
in rural areas.
 ► We lacked information on some potential confound-
ers, such as maternal viral load, and we can there-
fore not exclude residual/unmeasured confounding.
 ► We cannot exclude the possibility of selection 
bias due to the proportion of women with missing 
information.
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regimens.6 25–33 However, non-nucleoside reverse tran-
scriptase inhibitors (NNRTI), specifically NVP or 
efavirenz (EFV)-based HAARTs, are currently the first-
line drugs in resource-limited settings.5 The comparative 
safety of these treatment options during pregnancy is 
not clear, as studies comparing EFV-based HAART with 
NVP-based HAART reported inconsistent findings.23 34–36 
Moreover, the recommended type of HAART regimens, 
drug formulations and the frequency of drug intake 
have been regularly revised,4 which warrants additional 
studies comparing pregnancy outcomes according to 
different types of ART regimens. The role of timing of 
HAART initiation on risk of adverse pregnancy outcomes 
is also unclear. A recent systematic review and meta-anal-
ysis reported an increased risk of preterm birth and low 
birth weight associated with initiation of HAART before 
conception as compared with therapy initiation during 
pregnancy, but the review was limited by scarcity of studies 
reporting outcomes of interest.37
Ethiopia has a substantial disease burden of HIV/AIDS. 
It is estimated that 409 037 (1.5%) women in a reproduc-
tive age group were living with the virus in 2017.38 ZDV/
SD NVP was historically used as a prophylaxis to prevent 
mother-to-child transmission of HIV in Ethiopia when 
women are not eligible for HAART (CD4 count above 350 
cells/mm3 and WHO stages I and II). However, following 
the change in the WHO recommendation on treatment 
of HIV-infected pregnant women in 2013, the country 
recommended lifelong HAART to all HIV-infected preg-
nant women irrespective of immunological or clinical 
stage of disease.39 As a result, 67% of pregnant women 
with HIV received ART in 2017.40 There are no previous 
Ethiopian studies assessing the potential adverse effects 
of HAART exposure on pregnancy outcome. The objec-
tive of our study was therefore to compare pregnancy 
outcomes according to maternal ART regimens.
MethODs
Population and setting
We conducted a multicentre retrospective medical record 
review in three public hospitals and nine public health-
care centres in Addis Ababa city, Ethiopia. We extracted 
information on 2412 ART-exposed pregnancies to HIV-in-
fected women attending prenatal care follow-up between 
February 2010 and October 2016 by linking information 
from paper medical records (Antenatal Care Follow-up 
Form and Antiretroviral Treatment and Follow-up Form) 
and HIV clinics electronic ART databases. We excluded 
pregnancies with missing information about type of 
ART regimen, pregnancies where the ART regimen was 
changed during pregnancy, pregnancies exposed to ART 
for less than 2 weeks, pregnancies resulting in abortions 
(expulsion for fetus before 28 completed weeks) or 
multiple births and pregnancies with missing informa-
tion on both gestational age at birth and birth weight 
(figure 1). This left a total of 1663 pregnancies by 1611 
HIV-infected women available for analysis. Our sample 
size provided us with 80% power to detect an OR ranging 
from 1.3 to 1.6, given a baseline risk of 12% for preterm 
birth, 19% low birth weight and 32% small-for-gestation-
al-age taken from previous Ethiopian estimates.41 This 
historical medical record review study was regarded as 
clinical practice and outcome assessment and, therefore, 
did not require a signed informed consent.
Patient and public involvement
No patients were involved in setting the research ques-
tion, nor were they involved in developing plans for 
recruitment, design or implementation of the study. No 
patients were asked to advise on interpretation or writing 
up of results. There are no plans to disseminate the 
results of the research to study participants or the patient 
community.
Art exposure
We collected information on ART exposure during preg-
nancy from the Antiretroviral Treatment and Follow-up 
Form, which includes information on the type of ART 
initiated, in addition to clinical and immunological 
status. The form is completed by healthcare providers 
as part of the routine care of HIV-infected individuals. 
ART exposure was categorised as HAART before concep-
tion (initiated treatment before conception), HAART 
during pregnancy (initiated after conception) and ZDV 
monotherapy. HAART is composed of two nucleoside 
reverse-transcriptase inhibitors (NRTIs) and one NNRTI 
or PIs. We subsequently decomposed the group taking 
HAART to NVP-based HAART, EFV-based HAART and 
PI-based HAART. We also categorised HAART into teno-
fovir (TDF)-based HAART, ZDV-based HAART and other 
HAART regimens according to the NRTI components.
Figure 1 Flow diagram of inclusion and exclusion criteria. 
ART, antiretroviral therapy.
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Pregnancy outcomes
The primary pregnancy outcomes evaluated were 
preterm birth, low birth weight and small-for-gestation-
al-age. Preterm birth was defined as delivery before 37 
completed weeks of gestation and severe preterm birth 
as delivery before 32 completed weeks of gestation. 
Gestational age at birth was estimated based on ultraso-
nography (available for more than 75% of the pregnan-
cies), last menstruation period or fundal height. Low 
birth weight was defined as birth weight below 2500 g, 
while very low birth weight was defined as a birth weight 
below 1500 g.42 Small-for-gestational-age was calculated as 
weight below 10th percentile according to gestational age 
and sex-specific distributions using a WHO algorithm,43 
by incorporating sex-specific mean birth weight and SD 
from a previous national survey conducted in Ethiopia.44
Covariates
Additional information was gathered on maternal back-
ground characteristics likely to be associated with ART 
regimen and pregnancy outcomes. This include maternal 
age in years during the first prenatal care visit, marital 
status (married and others), education level (no educa-
tion, primary, secondary and college level education), 
history of stillbirth/abortion (yes or no), parity (catego-
rised as ‘0’, ‘1–2’ and ‘3 or more’) and maternal weight 
before conception or during the first trimester preg-
nancy in kg. Additional information was also gathered 
on haemoglobin (g/L), CD4 cell count (cells/mm3) and 
WHO clinical stages (stages I–IV) during the prenatal 
care follow-up.
statistical analysis
We compared the distribution of maternal background 
characteristics by the type of ART regimens using Χ2 
test or Fisher’s exact test for categorical variables and 
Kruskal-Wallis for continuous variables. We ran linear 
regression analysis to compare gestational age at birth 
and birth weight according to ART regimens, reporting 
mean difference and 95% CIs. We also ran three logistic 
regression models to compare adverse pregnancy 
outcomes according to ART regimens, reporting ORs 
and 95% CIs. First, we compared the risk of adverse preg-
nancy outcomes according to HAART during pregnancy, 
HAART before conception and ZDV monotherapy. 
Second, we compared adverse pregnancy outcomes 
according to different HAART regimens, categorising 
as EFV-based, NVP-based and PI-based HAART. Third, 
we compared adverse pregnancy outcomes according to 
HAART regimens categorised as TDF-based, ZDV-based 
and other HAART regimens. The multivariable analyses 
were adjusted for maternal age, weight, marital status, 
education, parity, CD4 cell count during pregnancy 
and WHO clinical stage during pregnancy. In addition, 
models comparing different HAART regimens were 
adjusted for timing of treatment initiation. Variables were 
categorised as indicated in table 1 and entered using 
dummy variables. Robust cluster variance estimation was 
used to account for the inclusion of multiple pregnancies 
from the same mother. In secondary analysis, the associa-
tion of year of birth with adverse pregnancy outcomes was 
evaluated by using Cuzick non-parametric test for trend. 
We also conducted sensitivity analyses restricting the 
analysis to pregnancies resulting in a live birth, pregnan-
cies exposed to HAART during pregnancy, pregnancies 
exposed to ART before 32 weeks of gestation and those 
with CD4 cell count of above 350 cells/mm3 at the time of 
pregnancy. The amount of missing information on indi-
vidual variables ranged from 2.0% (maternal age) to 30% 
(education). We therefore imputed a total of 20 data sets, 
using multiple imputations by chained equations. The 
model included the exposure variables, all covariates and 
outcomes. Categorisation of exposures and outcomes 
was done after imputation. The estimates across the 
imputed datasets were combined using Rubin’s rules.45 
The findings based on imputed data and complete-case 
analyses were largely similar. We report the findings based 
on the imputed data as the main results, while the find-
ings from the complete-case analysis are presented in 
the online Supplementary data. All p values presented 
are two-sided. The analyses were done using STATA V.13.
results
We included 1663 singleton pregnancies by 1611 HIV-in-
fected women in the analysis. Half, 826 (50%) of pregnan-
cies were exposed to HAART started before conception, 
638 (38%) were exposed to HAART initiated during 
pregnancy and 199 (12%) were exposed to ZDV mono-
therapy. Of those exposed to HAART, 852 (58%) were on 
EFV-based HAART and 580 (40%) were on NVP-based 
HAART. Based on the NRTI components, 1004 (69%) 
were TDF-based and 379 (26%) were ZDV-based HAART 
regimens. Women initiating HAART during pregnancy 
were younger, less likely to be multiparous and had lower 
CD4 count as compared with women initiating HAART 
before conception (table 1). Among women initiating 
HAART, women on EFV-based HAART were younger and 
less likely to be multiparous as compared with women 
on NVP-based HAART (table 1). Women who initiated 
HAART during pregnancy on average started treatment 
at 20 gestational weeks (SD=9), while women were placed 
on ZDV monotherapy at an average of 27 gestational 
weeks (SD=7). When we compared women who were 
included in the analysis to women who were excluded 
due to missing information on ART regimen and/or 
pregnancy outcomes, we found no significant differences 
in marital status, education, CD4 count or WHO stage at 
first visit (see online supplementary table 1).
The median gestational age at birth was 39.5 weeks (IQR 
37.7–41.0), while the median birth weight was 3.0 kg (IQR 
2.6–3.2). Of the total 1663 pregnancies included in the 
analysis, 277 (17%) resulted in preterm birth, 322 (19%) 
of the newborns were low birth weight, 538 (32%) of the 
newborns were small-for-gestational-age, while 98 (6%) of 
pregnancies resulted in stillbirth. Rate of preterm birth 
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was 17.9% in women initiating HAART during pregnancy, 
18% in women initiating HAART before conception and 
7% in women initiating ZDV monotherapy. The propor-
tion of low birth weight was 20.5% in women initiating 
HAART during pregnancy, 20.7% in women initiating 
HAART before conception and 10.1% in women initi-
ating ZDV monotherapy. Rate of small-for-gestational-age 
was 34% in women initiating HAART during pregnancy, 
33% in women initiating HAART before conception and 
25% in women initiating ZDV mono-therapy. Stillbirth rate 
was 5% in women initiating HAART during pregnancy, 
7% in women initiating HAART before conception and 
4% in women initiating ZDV monotherapy. Very preterm 
births (<32 gestational weeks) occurred in 4% and very low 
birth weight (<1500 g) in 2% of all pregnancies, but no 
significant differences in rates related to the different ART 
regimens.
In adjusted linear regression analysis, compared with 
infants exposed to HAART initiated during pregnancy, 
those exposed to ZDV monotherapy had on average 123 
g higher birth weight (adjusted mean difference=122.7, 
95% CI 28.7 to 216.0). Infants exposed to NVP-based 
HAART had lower gestational age at birth (adjusted 
mean difference=−4.2, 95% CI−7.4 to 0.9), and lower 
birth weight (adjusted mean difference=−78.0, 95% CI 
−152.3 to –3.8) compared with EFV-based HAART 
(see online supplementary table 2).
In the adjusted logistic regression analyses, compared 
with HAART initiated during pregnancy, ZDV mono-
therapy was less likely to result in preterm birth 
(adjusted OR 0.35, 95% CI 0.19 to 0.64) and low birth 
weight (adjusted OR 0.48, 95% CI 0.24 to 0.94), but not 
small-for-gestational-age (adjusted OR 0.74, 95% CI 0.48 
to 1.14) (table 2). Comparing HAART initiated during 
pregnancy with HAART initiated before conception indi-
cated no differential risk of preterm birth, low birth weight 
or small-for-gestational-age (table 2). The complete-case 
analysis showed largely similar results with the imputed 
analysis (see online supplementary table 3).
Evaluating pregnancies exposed to different categories 
of HAART indicated that NVP-based HAART was more 
likely to result in preterm birth (adjusted OR 1.44, 95% CI 
1.06 to 1.96), as compared with pregnancies exposed to 
EFV-based HAART (table 3). However, no differential risk 
of low birth weight and small-for-gestational-age was demon-
strated between EFV-based HAART, NVP-based HAART or 
PI-based HAART (table 3). Comparing TDF-based HAART 
with ZDV-based HAART showed no differential risk of 
preterm birth (adjusted OR 1.16, 95% CI 0.83 to 1.62), low 
birth weight (adjusted OR 0.99, 95% CI 0.69 to 1.42) or 
small-for-gestational-age (adjusted OR 0.92, 95% CI 0.66 to 
1.28) (table 3). The complete-case analyses showed largely 
similar results as the main analysis based on the imputed 
data (see online supplementary table 3).
The distribution of adverse pregnancy outcomes by 
year of birth was evaluated by Cuzick non-parametric test 
for trend. But we observed no differences in the propor-
tion of preterm birth (p=0.39), low birth weight (p=0.23) C
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or small-for-gestational-age (p=0.41) across year of birth 
(see online supplementary figure 1).
A sensitivity analysis excluding pregnancies resulting 
in a stillbirth (n=98) did not change our findings 
(see online supplementary table 4). Excluding women 
with a CD4 count below 351 cells/mm3 during preg-
nancy or pregnancies exposed to ART after 32 weeks of 
gestation did not substantially change the association 
between HAART during pregnancy and preterm birth 
as compared with ZDV monotherapy (see online supple-
mentary tables 5 and 6). Comparing NVP-based HAART 
with EFV-based HAART after excluding women who 
initiated HAART before conception did not substantially 
change the main finding (see online supplementary table 
7). We also conducted a sensitivity analysis adjusting for 
year of ART initiation, and the results were similar to what 
we observed in the main analysis (see online supplemen-
tary table 8). A sensitivity analysis adjusting for CD4 count 
at the time of treatment initiation, instead of adjusting 
for CD4 count during pregnancy yielded similar results 
to the main analysis (see online supplementary table 9).
DIsCussIOn
This study examining pregnancy outcomes according 
to ART regimens in resource-limited settings indicated 
that HIV-infected women who received HAART during 
pregnancy may have a higher risk of both preterm birth 
and low birthweight infants compared with those who 
received ZDV monotherapy. However, since we observed 
no strong evidence of an association of HAART initiated 
during pregnancy with small-for-gestational-age, the 
observed association with low birth weight is likely driven 
by the increased risk of preterm birth.
Our finding of a higher risk of preterm birth in 
pregnancies exposed to HAART initiated during preg-
nancy compared with ZDV monotherapy is in line with 
previous studies from sub-Saharan Africa6 10 13 and other 
low-income and middle-income countries.8 9 However, a 
multisite randomised controlled trial in Burkina Faso, 
Kenya and South Africa reported no increased risk of 
preterm birth associated with HAART initiated during 
pregnancy compared with ZDV monotherapy (13% 
vs 11%, p=0.39).19 There are studies reporting that an 
increased risk of preterm birth is limited to PI-based 
HAART.14–16 However, in our study, the majority (98%) 
of pregnancies were exposed to EFV-based or NVP-based 
HAART, indicating that the risk of preterm birth is not 
limited to PI-based HAART regimen.
We found that pregnancies exposed to NVP-based 
HAART had an increased risk of preterm birth compared 
with EFV-based HAART. Our finding supports the current 
WHO treatment guideline which recommends EFV-based 
HAART as a first-line treatment option as opposed to 
NVP-based HAART for all HIV-infected adults (including 
pregnant women). Before 2012, EFV-based HAARTs were 
avoided during early stage of pregnancy due to fear of 
increased risk of birth defects. After a sufficient amount 
of evidence indicated that the risk of birth defects was not 
elevated in pregnancies exposed to EFV-based HAARTs,46 47 
the WHO concluded that it is safe in early pregnancy.48 No 
evidence of differential risk of adverse pregnancy outcomes 
when EFV-based HAART was compared with PI-based 
HAART. However, the lack of association might be due to 
the small number of women on PI-based HAART. PI-based 
HAART was mostly used as second-line treatment in Ethi-
opia during the study period.
We observed no differential risk of preterm birth, 
low birth weight or small-for-gestational-age according 
to whether HAART was initiated before conception or 
during pregnancy. Our finding differs from a recent 
systematic review reporting a higher risk of preterm birth 
if HAART is initiated before conception as opposed to 
during pregnancy.37 In contrast to the systematic review, 
a study from Malawi reported lower incidence of preterm 
birth associated with initiation of HAART before concep-
tion.49 Previously, advanced disease stage or low level of 
immunity were criteria used to initiate HAART; there-
fore, the inconsistent findings regarding the associa-
tion between timing of HAART initiation with adverse 
pregnancy outcomes could be confounded by advanced 
disease stage or low level of immunity at the time of treat-
ment initiation.
There are different plausible biological mechanisms 
that could explain the positive association between 
HAART and adverse pregnancy outcomes. For any normal 
pregnancy to have a successful outcome, there should be 
a shift from Th1 cytokine production to Th2 cytokines.50 
HAART counteracts this natural shift in the immune 
system during pregnancy, which could contribute to an 
increased risk of preterm birth.50 An earlier study also 
reported that HAART was associated with placental insuf-
ficiency among HIV-infected women with stillbirth.51 The 
fact that we observed no strong evidence of an associa-
tion with small-for-gestational-age might indicate a less 
pronounced role of placental insufficiency.
HAART has multiple benefits in preventing mother-to-
child transmission of HIV,6 improving maternal clinical 
outcomes52 and preventing sexual transmission of HIV.53 
Currently, early initiation HAART for all HIV-infected indi-
viduals is gaining acceptance.5 54 And a growing number of 
HIV-infected women of reproductive age are on HAART 
in resource-limited settings,40 which may in turn increase 
the proportion of preterm and low birthweight infants. The 
difference in the rate of preterm birth (17.9 vs 7.0%) and 
low birth weight (20.5 vs 10.1%) between those exposed 
to HAART during pregnancy and ZDV monotherapy indi-
cates around a twofold increased risk. Preterm birth is the 
leading causes of neonatal death globally, and it is a contrib-
uting risk factor in over 50% of all neonatal deaths.55 This 
highlights the clinical relevance of our findings. The conse-
quences of an increase in preterm births and low birth 
weight are particularly severe in resource limited settings 
like Ethiopia, where the health systems lack capacity to 
manage such complications. It is well known that paedi-
atric and neonatal intensive care units in resource-limited 
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settings are scarce, and they lack the necessary equipment 
and skilled health professionals to provide adequate care to 
premature infants.
In the current study, we were able to account for a 
large number of potential confounders and performed 
sensitivity analyses to evaluate the robustness of the find-
ings. However, the study should be understood in light 
of the following limitations. The study was conducted 
in an urban area and may not be representative of rural 
settings. We were not able to account for maternal viral 
load, as this information was not available for the majority 
of the women. However, we did adjust for both CD4 
count and WHO clinical stage. Notably, previous studies 
reported that CD4 count was more predictive of birth 
outcomes than viral load.7 56 Only 32 (2%) pregnancies 
were exposed to PI-based HAART and 199 (12%) were 
exposed to ZDV monotherapy, which limits our conclu-
sion regarding these types of ARTs. Furthermore, PI-based 
HAART are second-line drugs in Ethiopia. We did not 
have information on whether the mothers had a history 
of adverse outcomes in previous pregnancies and could 
therefore not explore the potential role of confounding 
linked to adverse pregnancy outcomes in subsequent 
deliveries. Although sensitivity analyses excluding preg-
nancies exposed to HAART before conception, did not 
alter the main findings, confounding due to difference 
in maternal disease progression, nadir CD4 and immu-
nological ageing in the observed associations cannot be 
excluded. We cannot exclude the possibility that our 
findings are influenced by a selection bias due to the 
exclusion of 30% of the pregnancies as a result of missing 
information. However, the women excluded were similar 
to those included with regard to parity, CD4 count and 
WHO clinical stage. Due to the amount of missing infor-
mation, we conducted multiple imputations by chained 
equations. The results of imputed data and complete-case 
analysis were largely similar. We also relied on the registra-
tion of information by healthcare professionals and were 
unable to differentiate spontaneous and induced preterm 
term births. As in any observational study, we also cannot 
exclude the possibility of unmeasured confounding.
COnClusIOns
In this study from Ethiopia, we observed a higher risk of 
adverse pregnancy outcomes in pregnancies exposed to 
HAART compared with ZDV monotherapy. Furthermore, 
exposure to NVP-based HAART resulted in an increased 
risk of preterm birth compared with EFV-based HAART. 
Currently, the WHO recommends early initiation of 
HAART for all HIV-infected individuals. The capacity 
to monitor and manage adverse pregnancy outcomes in 
resource-limited healthcare settings should be improved 
to maximise the benefits of HAART and to minimise 
adverse pregnancy outcome risks. Additional prospec-
tive large-scale studies comparing pregnancy outcomes 
according to different HAART regimens are warranted.
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